4,390 Shares in AbbVie Inc. $ABBV Acquired by Directional Asset Management

Directional Asset Management purchased a new position in AbbVie Inc. (NYSE:ABBV) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 4,390 shares of the company’s stock, valued at approximately $1,003,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Diversified Trust Co raised its stake in AbbVie by 23.6% during the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after acquiring an additional 10,891 shares in the last quarter. Permanent Capital Management LP acquired a new position in shares of AbbVie during the 3rd quarter valued at $720,000. Railway Pension Investments Ltd increased its position in shares of AbbVie by 33.0% during the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after purchasing an additional 211,800 shares during the period. World Investment Advisors increased its position in shares of AbbVie by 9.4% during the 3rd quarter. World Investment Advisors now owns 113,925 shares of the company’s stock valued at $26,378,000 after purchasing an additional 9,811 shares during the period. Finally, Public Sector Pension Investment Board increased its position in shares of AbbVie by 17.0% during the 3rd quarter. Public Sector Pension Investment Board now owns 1,044,690 shares of the company’s stock valued at $241,888,000 after purchasing an additional 151,644 shares during the period. Institutional investors own 70.23% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.06% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a $1.4 billion, 185?acre advanced manufacturing campus in Durham, NC to produce immunology, neuroscience and oncology medicines; the investment is AbbVie’s largest single-site capital commitment and should support capacity, vertical integration and long?term growth. AbbVie to build $1.4 billion manufacturing campus in North Carolina
• Positive Sentiment: Canaccord initiated coverage with a strong?buy/Buy stance and a $262 price target, adding an analyst catalyst and incremental buy-side attention that may support near-term buying interest. AbbVie (ABBV): The Best Stock to Buy on a Pullback
• Positive Sentiment: AbbVie inked an exclusive licensing agreement with Haisco Pharmaceutical Group for pain?medicine development, extending its pipeline and potential future product/IP upside. AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development
• Neutral Sentiment: AbbVie is set to report Q1 2026 earnings on April 29; consensus estimates (Zacks) call for revenue around $14.78B and EPS near $2.69 — the print and management commentary could be a short?term volatility trigger. AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results?
• Neutral Sentiment: Media and investor pieces highlighting AbbVie as a “buy on a pullback” or attractive dividend/biotech play add background interest but are not immediate catalysts without fresh fundamentals or trial readouts. AbbVie (ABBV): The Best Stock to Buy on a Pullback (InsiderMonkey)
• Negative Sentiment: The U.S. FDA has declined to approve AbbVie’s trenibotulinumtoxinE (TrenibotE) wrinkle treatment, citing manufacturing issues — that regulatory setback delays potential cosmetic-market revenue and introduces execution risk around manufacturing remediation. US FDA declines to approve AbbVie’s wrinkle treatment (Reuters)
• Negative Sentiment: AbbVie confirmed receipt of a Complete Response Letter (CRL) from the FDA for the TrenibotE BLA related to manufacturing processes; while the agency did not request new clinical studies, fixing CMC (chemistry, manufacturing, controls) issues can be time?consuming and costly. AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

AbbVie Stock Up 0.2%

Shares of NYSE ABBV opened at $200.97 on Friday. The stock has a market capitalization of $355.34 billion, a price-to-earnings ratio of 85.15, a PEG ratio of 0.72 and a beta of 0.38. The stock’s fifty day simple moving average is $217.33 and its 200 day simple moving average is $222.62. AbbVie Inc. has a 52-week low of $176.11 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts anticipate that AbbVie Inc. will post 14.22 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is presently 293.22%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. The Goldman Sachs Group reiterated a “neutral” rating and set a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 11th. Royal Bank Of Canada assumed coverage on AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price target on the stock. Finally, Barclays assumed coverage on AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $253.19.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.